Wnt/Beta-Catenin Inhibitors Block SARS-CoV-2 Replication
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an urgent need for effective drugs that can prevent infection by SARS-CoV-2, as existing treatments are inadequate in addressing the global pandemic caused by this virus.
Innovation Solution
Administering therapeutically effective amounts of Wnt/β-catenin signaling inhibitors, PARP inhibitors, or compounds that increase peroxisome density in cells, such as IWP-O1, KYA1797K, Pyrvinium, and PPAR agonists, either alone or in combination with Molnupiravir or Remdesivir, to treat or prevent SARS-CoV-2 infection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used, then treatment options are limited, but effectiveness against SARS-CoV-2 is insufficient
Solution Approach 1:
The patent identifies Wnt/β-catenin pathway inhibitors as a multi-functional class of compounds that can treat multiple viral infections including SARS-CoV-2, influenza, and other pathogenic viruses. This universal approach expands treatment options beyond virus-specific therapies while maintaining high effectiveness through a shared mechanistic pathway.
Solution Approach 2:
The patent employs compounds that induce peroxisome biogenesis as a fundamental cellular parameter change. By increasing peroxisome density and enhancing the interferon response through this cellular reprogramming, the treatment achieves broad-spectrum antiviral effectiveness without requiring separate mechanisms for different viruses.
2Object-affected harmful factors
If Wnt/β-catenin pathway inhibitors are administered, then viral replication is reduced, but the mechanism involves complex cellular pathways
Solution Approach 1:
The patent extracts and targets a specific signaling pathway (Wnt/β-catenin) that regulates peroxisome biogenesis. By focusing on this single pathway rather than attempting to modulate multiple cellular processes simultaneously, the complex antiviral mechanism is simplified into a targeted therapeutic approach with a clear molecular entry point.
Solution Approach 2:
The patent employs pre-treatment with Wnt/β-catenin pathway inhibitors to establish enhanced peroxisome biogenesis and interferon responsiveness before viral infection occurs. This preliminary cellular reprogramming creates a pre-defense state that simplifies the overall treatment mechanism by preparing the cellular environment in advance rather than attempting to intervene during active viral replication.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These treatments significantly reduce SARS-CoV-2 viral titers and replication by enhancing peroxisome biogenesis and the interferon response, demonstrating potential as prophylactic and therapeutic options against SARS-CoV-2 and potentially other viral pathogens.
Implementation Method 1
enhancing peroxisome biogenesis and the interferon response
Implementation Method 2
enhancing peroxisome biogenesis and the interferon response
Data Source
AI summary
Use of Wnt/Beta-catenin pathway inhibitors to block replication of SARS-CoV-2 and other pathogenic viruses.